Director, Business Development at Iterative Health

Cambridge, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Healthcare, Biotechnology, Clinical Research, PharmaceuticalsIndustries

Requirements

8–10+ years of experience in life sciences, with a focus on clinical trials, medical affairs, business development, or enterprise partnerships
A robust network of decision-makers in the biotech and biopharma space
Track record of sourcing, structuring, and closing enterprise partnerships across the biopharma landscape
Skilled in external communications and relationship management
Entrepreneurial mindset with a high level of ownership and accountability
Comfortable working in a high-growth, fast-paced environment with cross-functional ambiguity
Experience in IBD, gastroenterology, immunology or adjacent therapeutic areas (preferred)
Deep understanding of the clinical trials landscape (preferred)
Advanced degree in healthcare or business (MBA, MPH, PhD) (preferred)

Responsibilities

Act as a primary external-facing representative of Iterative Health for prospective and existing life sciences partners
Develop, manage, and grow strategic relationships with biopharma and biotech organizations
Lead outbound and inbound business development efforts, from lead generation through contract execution
Support pricing, go-to-market strategy, and commercial input into clinical trial offerings
Partner with cross-functional internal teams to ensure delivery and performance align with partner expectations
Inform the evolution of our value proposition and positioning in the marketplace
Drive expansion within existing accounts and uncover new opportunities across the sponsor landscape
Represent Iterative Health at industry conferences and client meetings

Skills

Business Development

Strategic Partnerships

Lead Generation

Contract Negotiation

Go-to-Market Strategy

Pricing Strategy

Account Management

Clinical Trials

Biopharma

Biotech

Iterative Health

AI-driven solutions for gastrointestinal care

About Iterative Health

Iterative Health focuses on improving gastrointestinal (GI) care through the use of artificial intelligence (AI) and machine learning (ML). Their main product, SKOUT®, is an FDA-cleared device designed to help doctors detect adenomas, which are precursors to colorectal cancer. This device works alongside physician judgment to enhance the accuracy of diagnoses. In addition to SKOUT®, Iterative Health provides services that optimize clinical trials by using AI-enabled documentation technology, which improves patient care and ensures high-quality reporting across different healthcare institutions. This technology aims to make advanced care more accessible, especially to underserved populations. Unlike many competitors, Iterative Health combines AI technology with a strong focus on colorectal cancer prevention and clinical trial efficiency. The company's goal is to deliver top-tier GI care and improve health outcomes for patients worldwide.

Boston, MassachusettsHeadquarters

2017Year Founded

$182.1MTotal Funding

SERIES_BCompany Stage

AI & Machine Learning, HealthcareIndustries

51-200Employees

Benefits

Vision/Dental/ Medical Insurance

Life/Disability Insurance

Parental Leave

Stock Options

Flexible Work Hours

Unlimited Paid Time Off

Risks

Competition from tech giants in AI medical imaging threatens Iterative Health's market share.

Rapid expansion and partnerships may strain operational capabilities and resources.

Reliance on AI exposes Iterative Health to potential ethical and regulatory scrutiny.

Differentiation

Iterative Health uses AI to enhance GI care, focusing on colorectal cancer prevention.

Their SKOUT® device aids in adenoma detection, improving diagnostic accuracy in endoscopy.

AI-enabled documentation technology optimizes clinical trials, enhancing research quality and continuity.

Upsides

AI-driven predictive analytics in gastroenterology allow for personalized, effective patient care.

Partnerships with Gastro Health and One GI® expand clinical research capabilities in GI care.

$150M Series B funding accelerates AI innovations, transforming gastroenterology care.

Land your dream remote job 3x faster with AI

Try Jobo Free